Skip to main content
SpringerLink
Log in

Drug-Induced Skin, Nail and Hair Disorders

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Drug eruptions are among the most common adverse drug reactions, affecting approximately 3% of hospitalised patients. Although the rate of severe cutaneous adverse reactions to medications is low, these reactions can affect anyone who takes medication, and can result in death or disability. Two general patterns can be distinguished, depending on the type of onset of these cutaneous adverse drug reactions: acute or chronic. Acute-onset events are usually rather specific cutaneous ‘syndromes’ that constitute emergencies and should therefore be promptly recognised and treated, while chronic-onset events often present as dermatological diseases. The challenge is therefore to recognise the drug aetiology in front of a ‘classical’ dermatosis such as acne, lichen or pemphigus. Therefore, clinicians should carefully evaluate the signs or symptoms of all adverse reactions thought to be drug related, and discontinue the offending agent when feasible.

Erythematous drug eruptions are the most frequent and less severe acute immune drug-induced rashes, and are sometimes difficult to differentiate from viral eruptions. On the other hand, acute urticaria and angioedema are sometimes life-threatening eruptions for which a drug aetiology must be investigated. Photosensitivity, vasculitis and skin necrosis belong to the acute onset reactions, which are not always drug-induced, in contrast to fixed drug eruptions. The early recognition of acute generalised exanthematous pustulosis, DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome, Stevens-Johnson syndrome and toxic epidermal necrolysis are of high importance because of the specific mechanisms involved and the different prognosis of each of these diseases. Chronic onset drug-induced disorders include pigmentary changes, drug-induced autoimmune bullous diseases, lupus, pseudo lymphoma and acneiform eruptions; these are discussed, along with specific data on drug-induced hair and nail disorders.

As the disorders are numerous, the mechanisms and the drugs involved in the development of these various reactions are multiple. The list of drugs discussed in relation to the different disorders are as accurate as possible at the time of preparation of this review, but will need updating as new drugs emerge onto the market. We emphasize the clinical recognition, pathophysiology and treatment of skin, hair and nail adverse drug reactions, and the role of each doctor involved in the management of these patients in the notification of the adverse drug reaction to health authorities, using the minimal requirement for notification proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Lazarou J, Pomeranz BH, Covey PN. Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. JAMA 1998; 279: 1200–5

    Article  PubMed  CAS  Google Scholar 

  2. Arndt KA, Jick H. Rates of cutaneous reactions to drug: a report from the Boston Collaborative Drug Surveillance Program. JAMA 1976; 235: 918–23

    Article  PubMed  CAS  Google Scholar 

  3. Hunziker T, Künzi U, Braunschweig S, et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388–93

    Article  PubMed  CAS  Google Scholar 

  4. Caranasos GJ, May FE, Stewart RB, et al. Drug-associated deaths of medical inpatients. Arch Intern Med 1976; 136: 872–5

    Article  PubMed  CAS  Google Scholar 

  5. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587–91

    Article  PubMed  CAS  Google Scholar 

  6. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683–93

    PubMed  CAS  Google Scholar 

  7. Roujeau J-C, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994; 331: 1272–85

    Article  PubMed  CAS  Google Scholar 

  8. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquired Immune Defic Syndrome 1992; 5: 1237–57

    CAS  Google Scholar 

  9. Floret D. Clinical aspects of streptococcal and staphylococcal toxinic diseases. Arch Pediatr 2001; 8 Suppl. 4: 762S–8S

    Article  PubMed  Google Scholar 

  10. Gruchalla RS, Pirmohamed M. Clinical practice: antibiotic allergy. N Engl J Med 2006; 354: 601–9

    Article  PubMed  CAS  Google Scholar 

  11. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123–9

    Article  PubMed  CAS  Google Scholar 

  12. Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol 2006; 30: 19–23

    Article  PubMed  CAS  Google Scholar 

  13. Kozel MM, Mekkes JR, Bossuyt PM, et al. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134: 1575–80

    Article  PubMed  CAS  Google Scholar 

  14. Hedner T, Samuelsson O, Lunde H, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304: 941–6

    Article  PubMed  CAS  Google Scholar 

  15. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25: 345–72

    Article  PubMed  CAS  Google Scholar 

  16. Crowson AN, Mihm Jr MC, Magro CM. Cutaneous vasculitis: a review. J Cutan Pathol 2003; 30: 161–73

    Article  PubMed  Google Scholar 

  17. Jorg I, Fenyvesi T, Harenberg J. Anticoagulant-related skin reactions. Expert Opin Drug Saf 2002; 1: 287–94

    Article  PubMed  CAS  Google Scholar 

  18. Beylot C, Bioulac P, Doutre MS. Acute generalized exanthematic pustuloses (four cases) [in French]. Ann Dermatol Venereol 1980; 107: 37–48

    PubMed  CAS  Google Scholar 

  19. Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol 2001; 28: 113–9

    Article  PubMed  CAS  Google Scholar 

  20. Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433–41 1029

    Article  PubMed  CAS  Google Scholar 

  21. Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127: 1333–8

    Article  PubMed  CAS  Google Scholar 

  22. Knowles SR, Shapiro LE, Shear NH. Anticonvulsivant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21: 489–501

    Article  PubMed  CAS  Google Scholar 

  23. Callot V, Roujeau J-C, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome: two different clinical entities. Arch Dermatol 1996; 132: 1315–21

    Article  PubMed  CAS  Google Scholar 

  24. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82: 1826–32

    Article  PubMed  CAS  Google Scholar 

  25. Maguire JH, Wettrell G, Rane A. Apparently normal phenytoin metabolism in a patient with phenytoin-induced rash and lymphadenopathy. Br J Clin Pharmacol 1987; 24: 554–7

    Article  PubMed  CAS  Google Scholar 

  26. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug induced hypersensitivity syndrome. Br J Dermatol 1998; 139: 1026–32

    Article  PubMed  CAS  Google Scholar 

  27. Descamps V, Valance A, Edlinger C, et al. Association of herpesvirus 6 infection in drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301–4

    PubMed  CAS  Google Scholar 

  28. Begon E, Roujeau JC. Drug reaction with eosinophilia and systemic symptoms. Ann Dermatol Venereol 2004; 131: 293–7

    Article  PubMed  CAS  Google Scholar 

  29. Kauppinen K, Stubb S. Fixed eruptions: causative drugs and challenge tests. Br J Dermatol 1985; 112: 575–8

    Article  PubMed  CAS  Google Scholar 

  30. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990–1992): structure and results of a population based registry. J Clin Epidemiol 1996; 49: 769–73

    Article  PubMed  CAS  Google Scholar 

  31. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002; 14: 143–50

    Article  Google Scholar 

  32. Saíag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567–74

    Article  PubMed  Google Scholar 

  33. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocytes death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710–4

    Article  PubMed  CAS  Google Scholar 

  34. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–3

    Article  PubMed  CAS  Google Scholar 

  35. Wolkenstein P, Latarget J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586–9

    Article  PubMed  CAS  Google Scholar 

  36. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulphonamides and anticonvulsants. Arch Dermatol 1995; 131: 544–51

    Article  PubMed  CAS  Google Scholar 

  37. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens Johnson syndrome. Nature 2004; 428: 486

    Article  PubMed  CAS  Google Scholar 

  38. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005; 102: 4134–9

    Article  PubMed  CAS  Google Scholar 

  39. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92–6

    Article  PubMed  CAS  Google Scholar 

  40. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. SCAR Study Group. Arch Dermatol 2002; 138: 1019–24

    Article  PubMed  Google Scholar 

  41. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149–53

    Article  PubMed  CAS  Google Scholar 

  42. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272–6

    Article  PubMed  CAS  Google Scholar 

  43. Rabelink NM, Brakman M, Maartense E, et al. Erythema multiforme vs Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction. Ned Tijdschr Geneeskd 2003; 147: 2089–94

    PubMed  CAS  Google Scholar 

  44. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726–9

    PubMed  CAS  Google Scholar 

  45. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33–6

    Article  PubMed  CAS  Google Scholar 

  46. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7

    Article  PubMed  CAS  Google Scholar 

  47. Wintroub BU, Stern R. Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol 1985; 13: 167–79

    Article  PubMed  CAS  Google Scholar 

  48. Susser WS, Whitaker-Worth DL, Grant Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367–98

    Article  PubMed  CAS  Google Scholar 

  49. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998; 16: 393–7

    Article  PubMed  CAS  Google Scholar 

  50. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307–12

    Article  PubMed  CAS  Google Scholar 

  51. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control-study. Arch Dermatol 1996; 132: 272–6

    Article  PubMed  CAS  Google Scholar 

  52. Antonov D, Kazandjieva J, Etugov D, et al. Drug-induced lupus erythematosus. Clin Dermatol 2004; 22: 157–66

    Article  PubMed  Google Scholar 

  53. Souteyrand P, d’Incan M, Parent S. Misleading of rare cutaneous drug reactions. Rev Prat 2000; 50: 1329–33

    PubMed  CAS  Google Scholar 

  54. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491–500

    Article  PubMed  CAS  Google Scholar 

  55. Pillans PI, Woods DJ. Drug-associated alopecia. Int J Dermatol 1995; 34: 149–58

    Article  PubMed  CAS  Google Scholar 

  56. Tosi A, Misciali C, Piraccini BM, et al. Drug-induced hair loss and hair growth: incidence, management and avoidance. Drug Saf 1994; 10: 310–7

    Article  PubMed  CAS  Google Scholar 

  57. Faivre S, Delbado C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25–35

    Article  PubMed  CAS  Google Scholar 

  58. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201–6

    Article  PubMed  Google Scholar 

  59. Ward HA, Russo GG, Shrum J. Cutaneous manifestations of antiretroviral therapy. J Am Acad Dermatol 2002; 46: 284–93

    Article  PubMed  Google Scholar 

  60. Piraccini BM, Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 1999; 21: 187–201 1030

    Article  PubMed  CAS  Google Scholar 

  61. Hussain S, Anderson DN, Salvatti ME, et al. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000; 88: 2367–71

    Article  PubMed  CAS  Google Scholar 

  62. Chen GY, Chen YH, Hsu MM, et al. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001; 145: 521–2

    Article  PubMed  CAS  Google Scholar 

  63. Mehra A, Murphy RJ, Wilson BB. Idiopathic familial onychomadesis. J Am Acad Dermatol 2000; 43: 349–50

    Article  PubMed  CAS  Google Scholar 

  64. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984; 4: 677–8

    Article  Google Scholar 

  65. Tosti A, Pirraccini BM, D’Antuono A, et al. Paronychia associated with antiretroviral therapy. Br J Dermatol 1999; 140: 1165–8

    Article  PubMed  CAS  Google Scholar 

  66. Chang GC, Yang TY, Chen KC, et al. Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22(22): 4646–8

    Article  PubMed  Google Scholar 

  67. Boucher KW, Davidson K, Mirakhur B, et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 47: 632–3

    Article  PubMed  Google Scholar 

  68. Rahav G, Maayan S. Nail pigmentation associated with zidovudine: a review and report of a case. Scan J Infect Dis 1992; 24: 557–61

    Article  CAS  Google Scholar 

  69. Angeloni VL, Salasche SJ, Oriz R. Nail, skin and scleral pigmentation induced by minocycline. Cutis 1987; 40: 229–33

    PubMed  CAS  Google Scholar 

  70. Dixit VB, Chaudhary SD, Jain VK. Clofazimine-induced nail changes. Indian J Lepr 1989; 61: 476–8

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Roujeau has been a consultant for Medimmune, Pfizer, Sanofi-Aventis, OM Pharma, Cephalon, Serono, Boehringer-Ingelheim, LFB and Merck, and has received grants from Sanofi-Aventis, Bayer, Boehringer-Ingelheim, Novartis, Pfizer, GlaxoSmithKline, Servier and Wyeth. Drs Valeyrie-Allanore and Sassolas have no conflicts of interest that are directly relevant to the content of this review. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. University of Paris XII, Créteil, France

    Laurence Valeyrie-Allanore &  Jean-Claude Roujeau

  2. Department of Dermatology, Hôpital Henri Mondor, Créteil, 94010, France

    Laurence Valeyrie-Allanore &  Jean-Claude Roujeau

  3. University of Bretagne Occidentale, Brest, France

    Bruno Sassolas

  4. Department of Dermatology, C.H.U. Morvan, Brest, France

    Bruno Sassolas

Authors
  1. Laurence Valeyrie-Allanore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Sassolas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Claude Roujeau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Claude Roujeau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valeyrie-Allanore, L., Sassolas, B. & Roujeau, JC. Drug-Induced Skin, Nail and Hair Disorders. Drug-Safety 30, 1011–1030 (2007). https://doi.org/10.2165/00002018-200730110-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200730110-00003

Keywords

Search

Navigation